Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
Launched by ASTRAZENECA · Mar 16, 2004
Trial Information
Current as of June 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males or females at least 18 years of age.
- • Diagnosis of Zollinger-Ellison Syndrome or idiopathic hypersecretion
- Exclusion Criteria:
- • Pregnant or lactating females
- • History of drug addiction or alcohol abuse within 12 months prior to Screening.
- • History of intolerance to any proton pump inhibitors or any ingredient in their formulation.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Gainesville, Florida, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Paris, , France
King Of Prussia, Pennsylvania, United States
Clichy, , France
Saint Germain En Laye, , France
Patients applied
Trial Officials
Nexium Medical Science Director, MD
Study Director
AstraZeneca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials